Jagsonpal Pharmaceuticals extinguishes 16 lakh shares

2 min read     Updated on 03 Jun 2026, 02:39 AM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Jagsonpal Pharmaceuticals Limited extinguished 16,00,000 equity shares on June 02, 2026, pursuant to SEBI Buy-Back Regulations. The share capital reduced to ₹13,10,78,300, with promoter holding increasing to 69.36%.

powered bylight_fuzz_icon
41941736

*this image is generated using AI for illustrative purposes only.

Jagsonpal Pharmaceuticals Limited has extinguished 16,00,000 equity shares following the completion of its buyback offer on June 02, 2026. The extinguishment was carried out on a proportionate basis through the tender offer route pursuant to the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018. This corporate action reduces the total number of issued, subscribed, and fully paid-up equity shares from 6,71,39,150 to 6,55,39,150, bringing the post-buyback share capital to ₹13,10,78,300.

Share Capital Reconciliation

The reconciliation of the company's share capital pre and post-extinguishment confirms that all 16,00,000 shares bought back were in dematerialized form, with no shares tendered in physical form. The equity shares extinguished carry a face value of ₹2 each. The process was verified by the Registrar to the Buyback Offer, MCS Share Transfer Agent Limited, and certified by the company's Managing Director and Non-Executive Director in compliance with Regulation 11 of the Buyback Regulations.

Particulars No. of Equity Shares Amount (in ₹)
Pre-extinguishment: Issued, subscribed and fully paid-up share capital 6,71,39,150 13,42,78,300
Less: Equity Shares bought-back (Dematerialized Form) 16,00,000 32,00,000
Post extinguishment: Issued, subscribed and fully paid-up share capital 6,55,39,150 13,10,78,300

Depository Confirmations

National Securities Depository Limited (NSDL) executed the debit of 1,600,000 equity shares on May 27, 2026. Central Depository Services (India) Limited (CDSL) also confirmed the buyback, noting that the capital of the company recorded with CDSL post-buyback stands at ₹13,10,78,300. The extinguishment was finalized based on the public announcement dated April 28, 2026, and the letter of offer dated May 6, 2026.

Shareholding Pattern Post-Buyback

The extinguishment of shares has altered the shareholding pattern of the company. The Promoter and Promoter Group's holding has increased to 69.36% of the post-buyback equity share capital, while Foreign Investors now hold 30.64%. The total number of equity shares post-buyback stands at 6,55,39,150.

Category Pre-Buyback Shares % of Pre-Buyback Capital Post-Buyback Shares % of Post-Buyback Capital
Promoter / Promoter Group 4,54,58,210 67.71 4,54,58,210 69.36
Foreign Investors 22,37,115 3.33 2,00,80,940 30.64
Financial Institutions / Banks & Mutual Funds 4,30,091 0.64 - -
Others (Public, Public Bodies Corporate etc.) 1,90,13,734 28.32 - -
Total 6,71,39,150 100.00 6,55,39,150 100.00

Historical Stock Returns for Jagsonpal Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
+0.12%-2.84%-3.98%-7.23%-14.79%+294.05%

How will the significant increase in Foreign Investors' stake to 30.64% influence Jagsonpal's strategic direction and governance?

What impact will the reduced equity base have on the company's earnings per share (EPS) and future dividend payouts?

Will the company consider further capital allocation strategies, such as dividends or additional buybacks, given the promoter group's increased holding?

Jagsonpal Pharmaceuticals
View Company Insights
View All News
like17
dislike

Jagsonpal concludes ₹40 crore buyback at ₹250 per share

1 min read     Updated on 25 May 2026, 03:22 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Jagsonpal Pharmaceuticals Limited has successfully completed the buyback of 16,00,000 equity shares at ₹250 per share, totaling ₹40 crore. The offer, which closed on May 14, 2026, was subscribed 3.67 times, with settlement concluding on May 21, 2026. Post-buyback, the promoter holding increased to 69.36%.

powered bylight_fuzz_icon
41242077

*this image is generated using AI for illustrative purposes only.

Jagsonpal Pharmaceuticals Limited has successfully concluded its buyback process, which closed on May 14, 2026. The company bought back 16,00,000 fully paid-up equity shares, representing 2.39% of the total outstanding shares as on the record date of May 4, 2026. The buyback was executed through the Tender Offer route at a price of ₹250 per equity share, aggregating to a total consideration of ₹40,00,00,000, excluding transaction costs.

Buyback Details and Subscription

The offer received significant interest from shareholders, with the Registrar to the Buyback receiving 4,429 valid applications for 58,73,380 equity shares. This resulted in a subscription level of approximately 3.67 times the maximum number of shares proposed to be bought back. The acceptance ratio varied across categories, with the General Category for other Shareholders seeing a higher subscription rate compared to the Reserved Category for Small Shareholders.

Category of Shareholders No. of Equity Shares reserved No. of valid applications Total Equity Shares Validly Tendered Times Subscription
Reserved Category for Small Shareholders 2,40,975 3,932 6,40,435 2.66
General Category for other Shareholders 13,59,025 497 52,32,945 3.85
Total 16,00,000 4,429 58,73,380 3.67

Settlement and Capital Structure

The settlement of valid bids was completed by the Clearing Corporations on May 21, 2026, with funds directly paid out to eligible shareholders. Equity shares accepted under the buyback were transferred to the company's Demat Escrow Account on the same day. Consequently, the extinguishment of the 16,00,000 accepted shares is currently under process and is expected to be completed on or before June 2, 2026.

Post-buyback, the company's issued and subscribed paid-up capital stands at 6,55,39,150 equity shares of ₹2 each, amounting to ₹13,10,78,300. The promoter and promoter group holding has increased to 69.36% of the post-buyback equity share capital.

Major Shareholders

A significant portion of the buyback was accounted for by major shareholders. Entities holding more than 1% of the total equity shares bought back included Authum Investment And Infrastructure Limited, Manish Gupta, and Ashoka India Equity Investment Trust Plc. Collectively, the top nine shareholders accounted for 54.03% of the total equity shares bought back under the offer.

Historical Stock Returns for Jagsonpal Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
+0.12%-2.84%-3.98%-7.23%-14.79%+294.05%

How might the increased promoter holding of 69.36% post-buyback influence Jagsonpal Pharmaceuticals' corporate governance and future strategic decision-making?

Given the 3.67x oversubscription, could Jagsonpal Pharmaceuticals consider launching another buyback program in the near future to return additional capital to shareholders?

How will the reduction in outstanding shares impact Jagsonpal Pharmaceuticals' earnings per share and key valuation metrics going forward?

Jagsonpal Pharmaceuticals
View Company Insights
View All News
like20
dislike

More News on Jagsonpal Pharmaceuticals

1 Year Returns:-14.79%